ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Taste alterations in patients with cancer: an overview and recommendations for future research.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Personality traits are associated with the development and severity of chemosensory alterations during chemotherapy: a longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Optical Coherence Tomography Assessment of Tongue Papillary Atrophy and Patient-Reported Impact on Taste Following Head and Neck Cancer Therapy.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTaste alterations (TAs) are a common and distressing side effect experienced by patients with cancer. They significantly impact patients' nutritional intake, quality of life (QoL), and treatment outcomes. This narrative review explores the prevalence, mechanisms, and clinical implications of TAs in patients with cancer.
methodsAn online bibliographic search was performed across multiple electronic databases, including Medline via PubMed, Embase, Scopus, and Web of Science.
resultsTAs were across all treatment modalities and in treatment-naïve cancer patients. It is hypothesized that the mechanisms contributing to the development of TAs are multifactorial and may be associated with cancer itself or its therapies. The mechanisms include direct cytotoxic effects of cancer treatments, disruption of regenerative pathways, salivary gland dysfunction, and systemic inflammation. However, the exact mechanisms remain poorly understood. The management of TAs requires a multifaceted approach, including counselling and pharmacological interventions. Tailored nutritional strategies, such as oral nutritional supplements with patient-preferred flavors, can help address some sensory challenges and improve adherence to nutritional intervention and nutritional status. However, depending on the affected sensory modality and its severity, many sensory-adapted flavors showed limited effectiveness. Taste enhancers targeting specific taste receptors offer promising solutions to restore palatability.
conclusionTAs are an underrecognized challenge in cancer patients despite their impact on nutritional status and QoL. Addressing TAs should be an integral component of supportive care in oncology to optimize nutritional and treatment outcomes, as well as improve QoL and prognosis.
Indexed as
Identifiers
40804513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.